Adding abiraterone improves suppression of intraprostate androgensOctober 13, 2014Genitourinary Cancer
Hypofractionation, vessel-sparing RT techniques for prostate cancer yield good QOLOctober 10, 2014Genitourinary Cancer
Trials close in on optimal ADT duration in high-risk prostate cancerSeptember 24, 2014Genitourinary Cancer
Specific pattern of male baldness linked to aggressive prostate cancerSeptember 24, 2014Genitourinary Cancer
Benefit from adjuvant RT for men with lymph node invasive prostate cancer varies with tumor characteristicsSeptember 22, 2014Genitourinary Cancer
FDA approves enzalutamide for chemo-naive metastatic prostate cancerSeptember 11, 2014Genitourinary Cancer
Androgen deprivation should be continued indefinitely in men with metastatic castration-resistant prostate cancerSeptember 11, 2014Genitourinary Cancer
Blood marker may signal enzalutamide, abiraterone resistanceSeptember 3, 2014Genitourinary CancerPractice Management
PSA density predicts progression of low-risk prostate cancer during active surveillanceAugust 25, 2014Genitourinary Cancer
FDA panel recommends against approval of ultrasound therapy for early prostate cancerJuly 31, 2014Genitourinary Cancer
The Medical Roundtable: Prostate-Specific Antigen Screening for Prostate Cancer: Yes, No, or Maybe?July 30, 2014Genitourinary Cancer
